Sun Pharma launches dry eye treatment product in Canada
Sun Pharmaceutical Industries announced Thursday that its subsidiary has launched Cequa, a new treatment for dry eye disease, in Canada.
Sun Pharma Canada Inc, a wholly owned subsidiary of the Mumbai-based big pharma company, has launched Cequa (0.09% w/v Cyclosporine Ophthalmic Solution), a calcineurin inhibitor immunomodulator.
The product is the first dry eye treatment available in Canada that comes with nanomicellar technology (NCELL), which improves the bioavailability and physicochemical stability of cyclosporine to increase penetration into ocular tissues, Sun Pharma said in a statement. .
“We are thrilled to introduce CEQUA as a new treatment option for the more than six million Canadians living with dry eye disease,” said Sun Pharma North America CEO Abhay Gandhi.
This launch is an important milestone for the drugmaker as it expands its portfolio of ophthalmic products in Canada, he added.
The product demonstrates the company’s commitment to providing innovative medicines to support patient and physician choice, Gandhi said.
“Cequa, with its nanomicellar technology and the increased strength of cyclosporine, may be an important addition to our treatment options as eye care professionals strive for more personalized treatment,” W Bruce Jackson – MD, former professor and chair, Department of Ophthalmology, McGill University and the University of Ottawa – says.
Dry eye occurs when the quantity and/or quality of tears does not keep the surface of the eye properly lubricated. The disease causes a scratching sensation or a sensation that something is in the eye.
(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)